Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups
A total of 5 randomized, double-blind trials in patients with hypercholesterolemia were prospectively designed to allow pooling of plasma lipid data after 12 weeks of treatment. The purpose was (1) to compare rosuvastatin 5 and 10 mg with atorvastatin 10 mg (data from 3 of the 5 trials); (2) to comp...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2003-03, Vol.91 (5), p.3-10 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10 |
|---|---|
| container_issue | 5 |
| container_start_page | 3 |
| container_title | The American journal of cardiology |
| container_volume | 91 |
| creator | Blasetto, James W Stein, Evan A Brown, W.Virgil Chitra, Rohini Raza, Ali |
| description | A total of 5 randomized, double-blind trials in patients with hypercholesterolemia were prospectively designed to allow pooling of plasma lipid data after 12 weeks of treatment. The purpose was (1) to compare rosuvastatin 5 and 10 mg with atorvastatin 10 mg (data from 3 of the 5 trials); (2) to compare rosuvastatin 5 and 10 mg with simvastatin 20 mg and pravastatin 20 mg (data from 2 of the 5 trials); and (3) to summarize overall efficacy and subset analyses of rosuvastatin data from all 5 trials. Rosuvastatin 5 mg (n = 390) and 10 mg (n = 389) reduced low-density lipoprotein (LDL) cholesterol significantly more than did atorvastatin 10 mg (n = 393) (41.9% and 46.7% vs 36.4%, both p |
| doi_str_mv | 10.1016/S0002-9149(03)00003-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73109279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914903000031</els_id><sourcerecordid>325253931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-d553d84328a64c8a2dfa83af2b4f06a010a67ec7d4b98363f0002c1fb82546c03</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7rj6E5TgQfTQmq9Od06LLOsHLHhQzyGTVHaydHfapHtlfob_2JqdQcGLp6JSz1sp3peQ55y95Yzrd18ZY6IxXJnXTL7BhsmGPyAb3nem4YbLh2TzBzkjT2q9xZbzVj8mZ1xopaXUG_LrKsbknd_THGnJdb1zdXFLmqjP4-wKBPozLTualx0UehxV6hZaYQC_4BjfCj7e0JArVIrK3X6G4nd5gLpAwTImT2dUwrSgdgoHqM7gkxvonOd1wFme6E3J61yfkkfRDRWeneo5-f7h6tvlp-b6y8fPl--vG68UW5rQtjL0SoreaeV7J0J0vXRRbFVk2jHOnO7Ad0FtTS-1jAczPI_bXrRKeybPyavj3rnkHyueasdUPQyDmyCv1XaSMyM6g-DLf8DbvJYJb7NCMmmkMAqh9gh5NLEWiHYuaXRlbzmzh8DsfWD2kIZl0t4HZjnqXpyWr9sRwl_VKSEELo4AoBd3CYqtHo30EFLBAGzI6T9f_AY1Nqg4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230393294</pqid></control><display><type>article</type><title>Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Blasetto, James W ; Stein, Evan A ; Brown, W.Virgil ; Chitra, Rohini ; Raza, Ali</creator><creatorcontrib>Blasetto, James W ; Stein, Evan A ; Brown, W.Virgil ; Chitra, Rohini ; Raza, Ali</creatorcontrib><description>A total of 5 randomized, double-blind trials in patients with hypercholesterolemia were prospectively designed to allow pooling of plasma lipid data after 12 weeks of treatment. The purpose was (1) to compare rosuvastatin 5 and 10 mg with atorvastatin 10 mg (data from 3 of the 5 trials); (2) to compare rosuvastatin 5 and 10 mg with simvastatin 20 mg and pravastatin 20 mg (data from 2 of the 5 trials); and (3) to summarize overall efficacy and subset analyses of rosuvastatin data from all 5 trials. Rosuvastatin 5 mg (n = 390) and 10 mg (n = 389) reduced low-density lipoprotein (LDL) cholesterol significantly more than did atorvastatin 10 mg (n = 393) (41.9% and 46.7% vs 36.4%, both p <0.001). Treatment with rosuvastatin 5 mg (n = 240) and 10 mg (n = 226) also resulted in significantly greater reductions in LDL cholesterol compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (40.6% and 48.1% vs 27.1% and 35.7%, all p <0.001). Significant differences favoring rosuvastatin 10 mg were also observed for total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, apolipoprotein (apo) B, and apo A-I versus atorvastatin 10 mg, and for total cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and apo B versus simvastatin 20 mg and pravastatin 20 mg. Analyses of all the rosuvastatin 10 mg data (n = 615) from the 5 trials in subgroups defined by age ≥65 years, female sex, postmenopausal status, hypertension, atherosclerosis, type 2 diabetes, and obesity showed that rosuvastatin had consistent efficacy across patient subgroups.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/S0002-9149(03)00003-1</identifier><identifier>PMID: 12646336</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anticholesteremic Agents - administration & dosage ; Anticholesteremic Agents - therapeutic use ; Atorvastatin ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Clinical trials ; Coronary Disease - blood ; Coronary Disease - etiology ; Coronary Disease - prevention & control ; Double-Blind Method ; Drug Administration Schedule ; Drug therapy ; Effectiveness ; Female ; Fluorobenzenes - administration & dosage ; Fluorobenzenes - therapeutic use ; Heptanoic Acids - therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypercholesterolemia - blood ; Hypercholesterolemia - complications ; Hypercholesterolemia - drug therapy ; Least-Squares Analysis ; Male ; Middle Aged ; Multicenter Studies as Topic ; Pravastatin - therapeutic use ; Prospective Studies ; Pyrimidines ; Pyrroles - therapeutic use ; Randomized Controlled Trials as Topic ; Rosuvastatin Calcium ; Simvastatin - therapeutic use ; Sulfonamides ; Treatment Outcome</subject><ispartof>The American journal of cardiology, 2003-03, Vol.91 (5), p.3-10</ispartof><rights>2003 Excerpta Medica Inc.</rights><rights>Copyright Elsevier Sequoia S.A. Mar 6, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-d553d84328a64c8a2dfa83af2b4f06a010a67ec7d4b98363f0002c1fb82546c03</citedby><cites>FETCH-LOGICAL-c440t-d553d84328a64c8a2dfa83af2b4f06a010a67ec7d4b98363f0002c1fb82546c03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002914903000031$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12646336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Blasetto, James W</creatorcontrib><creatorcontrib>Stein, Evan A</creatorcontrib><creatorcontrib>Brown, W.Virgil</creatorcontrib><creatorcontrib>Chitra, Rohini</creatorcontrib><creatorcontrib>Raza, Ali</creatorcontrib><title>Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>A total of 5 randomized, double-blind trials in patients with hypercholesterolemia were prospectively designed to allow pooling of plasma lipid data after 12 weeks of treatment. The purpose was (1) to compare rosuvastatin 5 and 10 mg with atorvastatin 10 mg (data from 3 of the 5 trials); (2) to compare rosuvastatin 5 and 10 mg with simvastatin 20 mg and pravastatin 20 mg (data from 2 of the 5 trials); and (3) to summarize overall efficacy and subset analyses of rosuvastatin data from all 5 trials. Rosuvastatin 5 mg (n = 390) and 10 mg (n = 389) reduced low-density lipoprotein (LDL) cholesterol significantly more than did atorvastatin 10 mg (n = 393) (41.9% and 46.7% vs 36.4%, both p <0.001). Treatment with rosuvastatin 5 mg (n = 240) and 10 mg (n = 226) also resulted in significantly greater reductions in LDL cholesterol compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (40.6% and 48.1% vs 27.1% and 35.7%, all p <0.001). Significant differences favoring rosuvastatin 10 mg were also observed for total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, apolipoprotein (apo) B, and apo A-I versus atorvastatin 10 mg, and for total cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and apo B versus simvastatin 20 mg and pravastatin 20 mg. Analyses of all the rosuvastatin 10 mg data (n = 615) from the 5 trials in subgroups defined by age ≥65 years, female sex, postmenopausal status, hypertension, atherosclerosis, type 2 diabetes, and obesity showed that rosuvastatin had consistent efficacy across patient subgroups.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticholesteremic Agents - administration & dosage</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Atorvastatin</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Clinical trials</subject><subject>Coronary Disease - blood</subject><subject>Coronary Disease - etiology</subject><subject>Coronary Disease - prevention & control</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Effectiveness</subject><subject>Female</subject><subject>Fluorobenzenes - administration & dosage</subject><subject>Fluorobenzenes - therapeutic use</subject><subject>Heptanoic Acids - therapeutic use</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypercholesterolemia - blood</subject><subject>Hypercholesterolemia - complications</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Least-Squares Analysis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multicenter Studies as Topic</subject><subject>Pravastatin - therapeutic use</subject><subject>Prospective Studies</subject><subject>Pyrimidines</subject><subject>Pyrroles - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Rosuvastatin Calcium</subject><subject>Simvastatin - therapeutic use</subject><subject>Sulfonamides</subject><subject>Treatment Outcome</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2LFDEQhoMo7rj6E5TgQfTQmq9Od06LLOsHLHhQzyGTVHaydHfapHtlfob_2JqdQcGLp6JSz1sp3peQ55y95Yzrd18ZY6IxXJnXTL7BhsmGPyAb3nem4YbLh2TzBzkjT2q9xZbzVj8mZ1xopaXUG_LrKsbknd_THGnJdb1zdXFLmqjP4-wKBPozLTualx0UehxV6hZaYQC_4BjfCj7e0JArVIrK3X6G4nd5gLpAwTImT2dUwrSgdgoHqM7gkxvonOd1wFme6E3J61yfkkfRDRWeneo5-f7h6tvlp-b6y8fPl--vG68UW5rQtjL0SoreaeV7J0J0vXRRbFVk2jHOnO7Ad0FtTS-1jAczPI_bXrRKeybPyavj3rnkHyueasdUPQyDmyCv1XaSMyM6g-DLf8DbvJYJb7NCMmmkMAqh9gh5NLEWiHYuaXRlbzmzh8DsfWD2kIZl0t4HZjnqXpyWr9sRwl_VKSEELo4AoBd3CYqtHo30EFLBAGzI6T9f_AY1Nqg4</recordid><startdate>20030306</startdate><enddate>20030306</enddate><creator>Blasetto, James W</creator><creator>Stein, Evan A</creator><creator>Brown, W.Virgil</creator><creator>Chitra, Rohini</creator><creator>Raza, Ali</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20030306</creationdate><title>Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups</title><author>Blasetto, James W ; Stein, Evan A ; Brown, W.Virgil ; Chitra, Rohini ; Raza, Ali</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-d553d84328a64c8a2dfa83af2b4f06a010a67ec7d4b98363f0002c1fb82546c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticholesteremic Agents - administration & dosage</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Atorvastatin</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Clinical trials</topic><topic>Coronary Disease - blood</topic><topic>Coronary Disease - etiology</topic><topic>Coronary Disease - prevention & control</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Effectiveness</topic><topic>Female</topic><topic>Fluorobenzenes - administration & dosage</topic><topic>Fluorobenzenes - therapeutic use</topic><topic>Heptanoic Acids - therapeutic use</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypercholesterolemia - blood</topic><topic>Hypercholesterolemia - complications</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Least-Squares Analysis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multicenter Studies as Topic</topic><topic>Pravastatin - therapeutic use</topic><topic>Prospective Studies</topic><topic>Pyrimidines</topic><topic>Pyrroles - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Rosuvastatin Calcium</topic><topic>Simvastatin - therapeutic use</topic><topic>Sulfonamides</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blasetto, James W</creatorcontrib><creatorcontrib>Stein, Evan A</creatorcontrib><creatorcontrib>Brown, W.Virgil</creatorcontrib><creatorcontrib>Chitra, Rohini</creatorcontrib><creatorcontrib>Raza, Ali</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blasetto, James W</au><au>Stein, Evan A</au><au>Brown, W.Virgil</au><au>Chitra, Rohini</au><au>Raza, Ali</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2003-03-06</date><risdate>2003</risdate><volume>91</volume><issue>5</issue><spage>3</spage><epage>10</epage><pages>3-10</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>A total of 5 randomized, double-blind trials in patients with hypercholesterolemia were prospectively designed to allow pooling of plasma lipid data after 12 weeks of treatment. The purpose was (1) to compare rosuvastatin 5 and 10 mg with atorvastatin 10 mg (data from 3 of the 5 trials); (2) to compare rosuvastatin 5 and 10 mg with simvastatin 20 mg and pravastatin 20 mg (data from 2 of the 5 trials); and (3) to summarize overall efficacy and subset analyses of rosuvastatin data from all 5 trials. Rosuvastatin 5 mg (n = 390) and 10 mg (n = 389) reduced low-density lipoprotein (LDL) cholesterol significantly more than did atorvastatin 10 mg (n = 393) (41.9% and 46.7% vs 36.4%, both p <0.001). Treatment with rosuvastatin 5 mg (n = 240) and 10 mg (n = 226) also resulted in significantly greater reductions in LDL cholesterol compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (40.6% and 48.1% vs 27.1% and 35.7%, all p <0.001). Significant differences favoring rosuvastatin 10 mg were also observed for total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, apolipoprotein (apo) B, and apo A-I versus atorvastatin 10 mg, and for total cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and apo B versus simvastatin 20 mg and pravastatin 20 mg. Analyses of all the rosuvastatin 10 mg data (n = 615) from the 5 trials in subgroups defined by age ≥65 years, female sex, postmenopausal status, hypertension, atherosclerosis, type 2 diabetes, and obesity showed that rosuvastatin had consistent efficacy across patient subgroups.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>12646336</pmid><doi>10.1016/S0002-9149(03)00003-1</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2003-03, Vol.91 (5), p.3-10 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73109279 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Anticholesteremic Agents - administration & dosage Anticholesteremic Agents - therapeutic use Atorvastatin Cholesterol, HDL - blood Cholesterol, LDL - blood Clinical trials Coronary Disease - blood Coronary Disease - etiology Coronary Disease - prevention & control Double-Blind Method Drug Administration Schedule Drug therapy Effectiveness Female Fluorobenzenes - administration & dosage Fluorobenzenes - therapeutic use Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - blood Hypercholesterolemia - complications Hypercholesterolemia - drug therapy Least-Squares Analysis Male Middle Aged Multicenter Studies as Topic Pravastatin - therapeutic use Prospective Studies Pyrimidines Pyrroles - therapeutic use Randomized Controlled Trials as Topic Rosuvastatin Calcium Simvastatin - therapeutic use Sulfonamides Treatment Outcome |
| title | Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T23%3A15%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20rosuvastatin%20compared%20with%20other%20statins%20at%20selected%20starting%20doses%20in%20hypercholesterolemic%20patients%20and%20in%20special%20population%20groups&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Blasetto,%20James%20W&rft.date=2003-03-06&rft.volume=91&rft.issue=5&rft.spage=3&rft.epage=10&rft.pages=3-10&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/S0002-9149(03)00003-1&rft_dat=%3Cproquest_cross%3E325253931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230393294&rft_id=info:pmid/12646336&rft_els_id=S0002914903000031&rfr_iscdi=true |